메뉴 건너뛰기




Volumn 1, Issue 2, 2003, Pages 108-117

Metastatic bladder cancer: Role of chemotherapy and new agents

Author keywords

Bladder cancer; Chemotherapy; Cisplatin; Gemcitabine; Molecular targeted therapy; Novel or new agents; Paclitaxel; Urothelial cancer

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EDOTECARIN; EPOTHILONE B; EPOTHILONE D; ERLOTINIB; FMD 55900; GEFITINIB; GEMCITABINE; ICR 62; IFOSFAMIDE; LAPATINIB; LOBAPLATIN; LONAFARNIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PIRITREXIM; TIPIFARNIB; TRASTUZUMAB; TRIMETREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE;

EID: 2642517820     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9124(03)00019-9     Document Type: Article
Times cited : (6)

References (86)
  • 1
    • 0026625220 scopus 로고
    • A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study
    • Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1992;10:1066-73.
    • (1992) J Clin Oncol , vol.10 , pp. 1066-1073
    • Loehrer, P.1    Einhorn, L.H.2    Elson, P.J.3    Crawford, E.D.4    Kuebler, P.5    Tannock, I.6
  • 2
    • 0025297496 scopus 로고
    • A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors
    • Logothetis CJ, Dexeus F, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors. J Clin Oncol 1990;8:1050-5.
    • (1990) J Clin Oncol , vol.8 , pp. 1050-1055
    • Logothetis, C.J.1    Dexeus, F.2    Finn, L.3    Sella, A.4    Amato, R.J.5    Ayala, A.G.6
  • 3
    • 0021910302 scopus 로고
    • Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumors
    • Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumors. J Urol 1985;133:403-7.
    • (1985) J Urol , vol.133 , pp. 403-407
    • Sternberg, C.N.1    Yagoda, A.2    Scher, H.I.3    Watson, R.C.4    Ahmed, T.5    Weiselberg, L.R.6
  • 4
    • 0024817806 scopus 로고
    • M-VAC for advanced transitional cell carcinoma of the urothelium: Efficacy, and patterns of response and relapse
    • Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 1989;64:2448-58.
    • (1989) Cancer , vol.64 , pp. 2448-2458
    • Sternberg, C.N.1    Yagoda, A.2    Scher, H.I.3    Watson, R.C.4    Geller, N.5    Herr, H.W.6
  • 5
    • 0032795983 scopus 로고    scopus 로고
    • Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
    • Dodd PM, McCaffrey JA, Herr H, Mazumdar M, Bacik J, Higgins G, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Clin Oncol 1999;17(8):2546.
    • (1999) Clin Oncol , vol.17 , Issue.8 , pp. 2546
    • Dodd, P.M.1    McCaffrey, J.A.2    Herr, H.3    Mazumdar, M.4    Bacik, J.5    Higgins, G.6
  • 6
    • 0032887956 scopus 로고    scopus 로고
    • Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
    • Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17(10):3173-81.
    • (1999) J Clin Oncol , vol.17 , Issue.10 , pp. 3173-3181
    • Bajorin, D.F.1    Dodd, P.M.2    Mazumdar, M.3    Fazzari, M.4    McCaffrey, J.A.5    Scher, H.I.6
  • 7
    • 0030794516 scopus 로고    scopus 로고
    • Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
    • Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15(7):2564-9.
    • (1997) J Clin Oncol , vol.15 , Issue.7 , pp. 2564-2569
    • Saxman, S.B.1    Propert, K.J.2    Einhorn, L.H.3    Crawford, E.D.4    Tannock, I.5    Raghavan, D.6
  • 8
    • 0025906244 scopus 로고
    • Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
    • Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525-31.
    • (1991) Cancer , vol.67 , pp. 1525-1531
    • Geller, N.L.1    Sternberg, C.N.2    Penenberg, D.3    Scher, H.4    Yagoda, A.5
  • 9
    • 0036125840 scopus 로고    scopus 로고
    • Future directions for gemcitabine in the treatment of genitourinary cancer
    • Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. Sem Oncol 2002;29(1 Suppl 3):40-5.
    • (2002) Sem Oncol , vol.29 , Issue.1 SUPPL. 3 , pp. 40-45
    • Vogelzang, N.J.1
  • 10
    • 0036126022 scopus 로고    scopus 로고
    • Novel gemcitabine-containing triplets in the management of urothelial cancer
    • Hussain M, Vaishampayan U, Smith DC. Novel gemcitabine-containing triplets in the management of urothelial cancer. Sem Oncol 2002;29(1 Suppl 3):20-4.
    • (2002) Sem Oncol , vol.29 , Issue.1 SUPPL. 3 , pp. 20-24
    • Hussain, M.1    Vaishampayan, U.2    Smith, D.C.3
  • 11
    • 0034871427 scopus 로고    scopus 로고
    • Second-line treatment of advanced transitional cell carcinoma of the urothelial tract
    • Sternberg CN. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Curr Opin Urol 2001;11(5):523-9.
    • (2001) Curr Opin Urol , vol.11 , Issue.5 , pp. 523-529
    • Sternberg, C.N.1
  • 12
    • 0036675237 scopus 로고    scopus 로고
    • New drugs and new approaches for the treatment of metastatic urothelial cancer
    • Calabrò F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 2002;20(3):158-66.
    • (2002) World J Urol , vol.20 , Issue.3 , pp. 158-166
    • Calabrò, F.1    Sternberg, C.N.2
  • 13
    • 0036739839 scopus 로고    scopus 로고
    • High-risk metastatic urothelial cancer: Chances for cure?
    • Calabrò F, Sternberg CN. High-risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 2002;12(5):441-8.
    • (2002) Curr Opin Urol , vol.12 , Issue.5 , pp. 441-448
    • Calabrò, F.1    Sternberg, C.N.2
  • 14
    • 0033956528 scopus 로고    scopus 로고
    • Gemcitabine in bladder cancer
    • Sternberg CN. Gemcitabine in bladder cancer. Sem Oncol 2000;27(1):31-9.
    • (2000) Sem Oncol , vol.27 , Issue.1 , pp. 31-39
    • Sternberg, C.N.1
  • 15
    • 0036882090 scopus 로고    scopus 로고
    • The role of systemic chemotherapy in the management of muscle-invasive bladder cancer
    • Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3(12):738-47.
    • (2002) Lancet Oncol , vol.3 , Issue.12 , pp. 738-747
    • Juffs, H.G.1    Moore, M.J.2    Tannock, I.F.3
  • 16
    • 0026746316 scopus 로고
    • Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy
    • Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992;70:1974-9.
    • (1992) Cancer , vol.70 , pp. 1974-1979
    • Bellmunt, J.1    Albanell, J.2    Gallego, O.S.3    Ribas, A.4    Vicente, P.5    Carulla, J.6
  • 17
    • 0027482017 scopus 로고
    • Carboplatin-based chemotherapy for bladder cancer
    • Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 1993;19(Suppl C):21-5.
    • (1993) Cancer Treat Rev , vol.19 , Issue.SUPPL. C , pp. 21-25
    • Waxman, J.1    Barton, C.2
  • 18
    • 0030865381 scopus 로고    scopus 로고
    • Lobaplatin in advanced urothelial tract tumors
    • The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC)
    • Sternberg CN, de Mulder P, Fossa S, Kaye S, Roberts T, Pawinsky A, et al. Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Ann Oncol 1997;8(7):695-6.
    • (1997) Ann Oncol , vol.8 , Issue.7 , pp. 695-696
    • Sternberg, C.N.1    De Mulder, P.2    Fossa, S.3    Kaye, S.4    Roberts, T.5    Pawinsky, A.6
  • 19
    • 13844295293 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic trial of oxaliplatin and gemcitabine in patients with solid tumours
    • Abstract
    • Mitchell P, Links M, Galettis P, Desai J, Zimet A, de Boer R, et al. A phase I and pharmacokinetic trial of oxaliplatin and gemcitabine in patients with solid tumours. Proc Amer Soc Clin Oncol 2002;21 [Abstract].
    • (2002) Proc Amer Soc Clin Oncol , pp. 21
    • Mitchell, P.1    Links, M.2    Galettis, P.3    Desai, J.4    Zimet, A.5    De Boer, R.6
  • 20
    • 0028174048 scopus 로고
    • An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma
    • Witte RS, Elson P, Khandekar J. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 1994;73:688-92.
    • (1994) Cancer , vol.73 , pp. 688-692
    • Witte, R.S.1    Elson, P.2    Khandekar, J.3
  • 21
    • 0027463227 scopus 로고
    • Oral piritrexim, an effective treatment for metastatic urothelial cancer
    • de Wit R, Kayne SB, Robert JT, et al. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 1993;67:388-90.
    • (1993) Br J Cancer , vol.67 , pp. 388-390
    • De Wit, R.1    Kayne, S.B.2    Robert, J.T.3
  • 22
    • 0030927578 scopus 로고    scopus 로고
    • Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder
    • Khorsand M, Lange J, Feun L, et al. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 1997;15:157-63.
    • (1997) Invest New Drugs , vol.15 , pp. 157-163
    • Khorsand, M.1    Lange, J.2    Feun, L.3
  • 23
    • 0036125895 scopus 로고    scopus 로고
    • Brief communication: Use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer
    • Misset JL. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin Oncol 2002;29(1 Suppl 3):36-9.
    • (2002) Semin Oncol , vol.29 , Issue.1 SUPPL. 3 , pp. 36-39
    • Misset, J.L.1
  • 24
    • 0034861227 scopus 로고    scopus 로고
    • Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors
    • Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6(4):363-73.
    • (2001) Oncologist , vol.6 , Issue.4 , pp. 363-373
    • Hanauske, A.R.1    Chen, V.2    Paoletti, P.3    Niyikiza, C.4
  • 25
    • 0036261415 scopus 로고    scopus 로고
    • Future directions in the development of pemetrexed
    • Calvert H, Bunn Jr PA. Future directions in the development of pemetrexed. Sem Oncol 2002;29(2 Suppl 5):54-61.
    • (2002) Sem Oncol , vol.29 , Issue.2 SUPPL. 5 , pp. 54-61
    • Calvert, H.1    Bunn Jr., P.A.2
  • 26
    • 0001124267 scopus 로고    scopus 로고
    • A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder
    • Abstract
    • Paz-Ares L, Tabernero J, Moyano A, Rifa J, Gomez H, Marcuello E, et al. A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder. Proc Annu Meet Am Soc Clin Oncol 1998;17:339a [Abstract].
    • (1998) Proc Annu Meet Am Soc Clin Oncol , vol.17
    • Paz-Ares, L.1    Tabernero, J.2    Moyano, A.3    Rifa, J.4    Gomez, H.5    Marcuello, E.6
  • 27
    • 0036261858 scopus 로고    scopus 로고
    • Folate status and the safety profile of antifolates
    • Calvert H. Folate status and the safety profile of antifolates. Sem Oncol 2002;29(2 Suppl 5):3-7.
    • (2002) Sem Oncol , vol.29 , Issue.2 SUPPL. 5 , pp. 3-7
    • Calvert, H.1
  • 28
    • 0037678524 scopus 로고    scopus 로고
    • Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers
    • Ref Type: In Press
    • Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003. Ref Type: In Press.
    • (2003) Crit Rev Oncol Hematol
    • Sternberg, C.N.1    Vogelzang, N.J.2
  • 29
    • 0033857218 scopus 로고    scopus 로고
    • Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
    • von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068-77.
    • (2000) J Clin Oncol , vol.18 , Issue.17 , pp. 3068-3077
    • Von Der Maase, H.1    Hansen, S.W.2    Roberts, J.T.3    Dogliotti, L.4    Oliver, T.5    Moore, M.J.6
  • 30
    • 0027999651 scopus 로고
    • Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group
    • Roth BJ, Dreicer R, Einhorn LH. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12(11):2264-70.
    • (1994) J Clin Oncol , vol.12 , Issue.11 , pp. 2264-2270
    • Roth, B.J.1    Dreicer, R.2    Einhorn, L.H.3
  • 31
    • 0029853721 scopus 로고    scopus 로고
    • Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy
    • Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996;156(5):1606-8.
    • (1996) J Urol , vol.156 , Issue.5 , pp. 1606-1608
    • Dreicer, R.1    Gustin, D.M.2    See, W.A.3    Williams, R.D.4
  • 32
    • 0002575775 scopus 로고    scopus 로고
    • Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer
    • Abstract
    • Murphy BA, Johnson DR, Smith J, Koch M, et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Amer Soc Clin Oncol 1996;15 [Abstract].
    • (1996) Proc Amer Soc Clin Oncol , pp. 15
    • Murphy, B.A.1    Johnson, D.R.2    Smith, J.3    Koch, M.4
  • 33
    • 0033994219 scopus 로고    scopus 로고
    • Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study
    • Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000;18(5):1058-61.
    • (2000) J Clin Oncol , vol.18 , Issue.5 , pp. 1058-1061
    • Dreicer, R.1    Manola, J.2    Roth, B.J.3    Cohen, M.B.4    Hatfield, A.K.5    Wilding, G.6
  • 34
    • 0033789641 scopus 로고    scopus 로고
    • Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC)
    • Burch PA, Richardson RL, Cha SS, Sargent DJ, Pitot HC, Kaur JS, et al. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC). J Urol 2000;164:1538-42.
    • (2000) J Urol , vol.164 , pp. 1538-1542
    • Burch, P.A.1    Richardson, R.L.2    Cha, S.S.3    Sargent, D.J.4    Pitot, H.C.5    Kaur, J.S.6
  • 35
    • 0031005761 scopus 로고    scopus 로고
    • Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma
    • McCaffrey JA, Hilton S, Mazumdar M. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15(5):1853-7.
    • (1997) J Clin Oncol , vol.15 , Issue.5 , pp. 1853-1857
    • McCaffrey, J.A.1    Hilton, S.2    Mazumdar, M.3
  • 36
    • 0031786379 scopus 로고    scopus 로고
    • Docetaxel (Taxotere): An active agent in metastatic urothelial cancer results of a phase II study in non-chemotherapy pretreated patients
    • de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer results of a phase II study in non-chemotherapy pretreated patients. Br J Cancer 1998;78(10):1342-5.
    • (1998) Br J Cancer , vol.78 , Issue.10 , pp. 1342-1345
    • De Wit, R.1    Kruit, W.H.2    Stoter, G.3    De Boer, M.4    Kerger, J.5    Verweij, J.6
  • 37
    • 0031752909 scopus 로고    scopus 로고
    • Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study
    • Sengelov L, Kamby C, Lund B, Engelholm SA. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998;16(10):3392-7.
    • (1998) J Clin Oncol , vol.16 , Issue.10 , pp. 3392-3397
    • Sengelov, L.1    Kamby, C.2    Lund, B.3    Engelholm, S.A.4
  • 38
    • 0032779101 scopus 로고    scopus 로고
    • Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative
    • Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative. Ann Oncol 1999;10(11):1385-8.
    • (1999) Ann Oncol , vol.10 , Issue.11 , pp. 1385-1388
    • Dimopoulos, M.A.1    Bakoyannis, C.2    Georgoulias, V.3    Papadimitriou, C.4    Moulopoulos, L.A.5    Deliveliotis, C.6
  • 39
    • 18244396648 scopus 로고    scopus 로고
    • Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
    • Garcia del Muro X, Marcuello E, Guma J, Paz-Ares L, Climent MA, Carles J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002;86(3):326-30.
    • (2002) Br J Cancer , vol.86 , Issue.3 , pp. 326-330
    • Garcia Del Muro, X.1    Marcuello, E.2    Guma, J.3    Paz-Ares, L.4    Climent, M.A.5    Carles, J.6
  • 40
    • 0034741810 scopus 로고    scopus 로고
    • Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities
    • Fahy J. Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des 2001;7(13):1181-97.
    • (2001) Curr Pharm Des , vol.7 , Issue.13 , pp. 1181-1197
    • Fahy, J.1
  • 41
    • 0034517147 scopus 로고    scopus 로고
    • Preclinical and clinical trials of topoisomerase inhibitors
    • Saijo N. Preclinical and clinical trials of topoisomerase inhibitors. Ann NY Acad Sci 2000;922:92-9.
    • (2000) Ann NY Acad Sci , vol.922 , pp. 92-99
    • Saijo, N.1
  • 42
    • 0033199091 scopus 로고    scopus 로고
    • Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I
    • Yoshinari T, Ohkubo M, Fukasawa K, Egashira S, Hara Y, Matsumoto M, et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999;59(17):4271-5.
    • (1999) Cancer Res , vol.59 , Issue.17 , pp. 4271-4275
    • Yoshinari, T.1    Ohkubo, M.2    Fukasawa, K.3    Egashira, S.4    Hara, Y.5    Matsumoto, M.6
  • 43
    • 0034884824 scopus 로고    scopus 로고
    • Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D- glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts
    • Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2- hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]- pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 2001;48(3):250-4.
    • (2001) Cancer Chemother Pharmacol , vol.48 , Issue.3 , pp. 250-254
    • Cavazos, C.M.1    Keir, S.T.2    Yoshinari, T.3    Bigner, D.D.4    Friedman, H.S.5
  • 44
    • 0035873915 scopus 로고    scopus 로고
    • Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors
    • European Organization for Research and Treatment of Cancer. Protocol No. 30924
    • Sternberg CN, de Mulder PHM, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors. European Organization for Research and Treatment of Cancer. Protocol No. 30924. J Clin Oncol 2001;19(10):2638-46.
    • (2001) J Clin Oncol , vol.19 , Issue.10 , pp. 2638-2646
    • Sternberg, C.N.1    De Mulder, P.H.M.2    Schornagel, J.H.3    Théodore, C.4    Fossa, S.D.5    Van Oosterom, A.T.6
  • 45
    • 0036199749 scopus 로고    scopus 로고
    • The management of bladder cancer in the elderly
    • Sternberg CN, Calabrò F. The management of bladder cancer in the elderly. Tumori 2002;88(1 Suppl 1):S128-9.
    • (2002) Tumori , vol.88 , Issue.1 SUPPL. 1
    • Sternberg, C.N.1    Calabrò, F.2
  • 46
    • 0034773203 scopus 로고    scopus 로고
    • A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer
    • Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur J Cancer 2001;37(17):2212-5.
    • (2001) Eur J Cancer , vol.37 , Issue.17 , pp. 2212-2215
    • Bellmunt, J.1    De Wit, R.2    Albanell, J.3    Baselga, J.4
  • 47
    • 0036125648 scopus 로고    scopus 로고
    • Gemcitabine doublets in advanced urothelial cancer
    • Stadler WM. Gemcitabine doublets in advanced urothelial cancer. Sem Oncol 2002;29(1 Suppl 3):15-9.
    • (2002) Sem Oncol , vol.29 , Issue.1 SUPPL. 3 , pp. 15-19
    • Stadler, W.M.1
  • 48
    • 0342758712 scopus 로고    scopus 로고
    • Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional cell carcinoma: The importance of survival as a clinical trial end point
    • Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000;18(13):2537-44.
    • (2000) J Clin Oncol , vol.18 , Issue.13 , pp. 2537-2544
    • Small, E.J.1    Lew, D.2    Redman, B.G.3    Petrylak, D.P.4    Hammond, N.5    Gross, H.M.6
  • 49
    • 0031962154 scopus 로고    scopus 로고
    • Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regiment
    • Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regiment. J Clin Oncol 1998;16(1):255-60.
    • (1998) J Clin Oncol , vol.16 , Issue.1 , pp. 255-260
    • Vaughn, D.J.1    Malkowicz, S.B.2    Zoltick, B.3    Mick, R.4    Ramchandani, P.5    Holroyde, C.6
  • 50
    • 0031803705 scopus 로고    scopus 로고
    • Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
    • Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998;16(5):1844-8.
    • (1998) J Clin Oncol , vol.16 , Issue.5 , pp. 1844-1848
    • Redman, B.G.1    Smith, D.C.2    Flaherty, L.3    Du, W.4    Hussain, M.5
  • 51
    • 0035892761 scopus 로고    scopus 로고
    • Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy
    • [51 ] Sternberg CN, Calabrò F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92(12):2993-8.
    • (2001) Cancer , vol.92 , Issue.12 , pp. 2993-2998
    • Sternberg, C.N.1    Calabrò, F.2    Pizzocaro, G.3    Marini, L.4    Schnetzer, S.5    Sella, A.6
  • 52
    • 0035876046 scopus 로고    scopus 로고
    • Paclitaxel and gemcitabine chemotherapy for adanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network
    • Meluch AA, Greco FA, Burris III HA, O'Rourke T, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for adanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001;19(12):3018-24.
    • (2001) J Clin Oncol , vol.19 , Issue.12 , pp. 3018-3024
    • Meluch, A.A.1    Greco, F.A.2    Burris III, H.A.3    O'Rourke, T.4    Ortega, G.5    Steis, R.G.6
  • 53
    • 0013240227 scopus 로고    scopus 로고
    • A hossier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder
    • Abstract
    • Parameswaran R, Fisch MJ, Ansari RH, Fox EP, Sweeney CJ, Einhorn LH. A hossier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Annu Meet Am Soc Clin Oncol 2001;20(1):200a [Abstract].
    • (2001) Proc Annu Meet Am Soc Clin Oncol , vol.20 , Issue.1
    • Parameswaran, R.1    Fisch, M.J.2    Ansari, R.H.3    Fox, E.P.4    Sweeney, C.J.5    Einhorn, L.H.6
  • 54
    • 0003365848 scopus 로고    scopus 로고
    • Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies
    • Abstract
    • Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. Proc Annu Meet Am Soc Clin Oncol 2002;21(2):150b [Abstract].
    • (2002) Proc Annu Meet Am Soc Clin Oncol , vol.21 , Issue.2
    • Guardino, A.E.1    Srinivas, S.2
  • 55
    • 0010422261 scopus 로고    scopus 로고
    • Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma
    • Abstract
    • Fechner GH, Siener R, Reimann M, Strunk R, Golinski C, Heimbach D, et al. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J Urol 2002;167(4 Suppl):284 [Abstract].
    • (2002) J Urol , vol.167 , Issue.4 SUPPL. , pp. 284
    • Fechner, G.H.1    Siener, R.2    Reimann, M.3    Strunk, R.4    Golinski, C.5    Heimbach, D.6
  • 56
    • 4244198798 scopus 로고    scopus 로고
    • Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): A completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC)
    • Abstract
    • Kaufmann DS, Carducci MA, Kuzel T, Todd MB, Raghavan D, Oh WK, et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Annu Meet Am Soc Clin Oncol 2002;21(1):192a [Abstract].
    • (2002) Proc Annu Meet Am Soc Clin Oncol , vol.21 , Issue.1
    • Kaufmann, D.S.1    Carducci, M.A.2    Kuzel, T.3    Todd, M.B.4    Raghavan, D.5    Oh, W.K.6
  • 57
    • 0000568613 scopus 로고    scopus 로고
    • Gemcitabine and docetaxel in advanced carcinoma of the urothelium: Reporto of a phase II Eastern Cooperative Oncology Group trial
    • Manola JB, Dreicer R, Wilding G. Gemcitabine and docetaxel in advanced carcinoma of the urothelium: reporto of a phase II Eastern Cooperative Oncology Group trial. Proc Annu Meet Am Soc Clin Oncol 2002;21(1):200a.
    • (2002) Proc Annu Meet Am Soc Clin Oncol , vol.21 , Issue.1
    • Manola, J.B.1    Dreicer, R.2    Wilding, G.3
  • 58
    • 0036052170 scopus 로고    scopus 로고
    • Triplet Combination Chemotherapy Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer
    • Bellmunt J, Cos J, Cleries R, Perez M, Ribas A, Eres N, et al. Triplet Combination Chemotherapy Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 2002;20(5-6):673-85.
    • (2002) Cancer Invest , vol.20 , Issue.5-6 , pp. 673-685
    • Bellmunt, J.1    Cos, J.2    Cleries, R.3    Perez, M.4    Ribas, A.5    Eres, N.6
  • 59
    • 0034666030 scopus 로고    scopus 로고
    • Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
    • Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Charles J, Batiste-Alentorn E, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000;18(18):3247-55.
    • (2000) J Clin Oncol , vol.18 , Issue.18 , pp. 3247-3255
    • Bellmunt, J.1    Guillem, V.2    Paz-Ares, L.3    González-Larriba, J.L.4    Charles, J.5    Batiste-Alentorn, E.6
  • 61
    • 0035339940 scopus 로고    scopus 로고
    • Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer
    • Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19(9):2527-33.
    • (2001) J Clin Oncol , vol.19 , Issue.9 , pp. 2527-2533
    • Hussain, M.1    Vaishampayan, U.2    Du, W.3    Redman, B.4    Smith, D.C.5
  • 62
    • 0034177933 scopus 로고    scopus 로고
    • Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules
    • Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000;88(7):1671-8.
    • (2000) Cancer , vol.88 , Issue.7 , pp. 1671-1678
    • Bajorin, D.F.1    McCaffrey, J.A.2    Dodd, P.M.3    Hilton, S.4    Mazumdar, M.5    Kelly, W.K.6
  • 63
    • 0033956934 scopus 로고    scopus 로고
    • Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract
    • Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol 2000;18(4):840-6.
    • (2000) J Clin Oncol , vol.18 , Issue.4 , pp. 840-846
    • Dodd, P.M.1    McCaffrey, J.A.2    Hilton, S.3    Mazumdar, M.4    Herr, H.5    Kelly, W.K.6
  • 64
    • 0034614637 scopus 로고    scopus 로고
    • The hallmarks of cancer
    • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
    • (2000) Cell , vol.100 , Issue.1 , pp. 57-70
    • Hanahan, D.1    Weinberg, R.A.2
  • 65
    • 0034795435 scopus 로고    scopus 로고
    • Farnesyl transferase inhibitors - A novel therapy for breast cancer
    • Johnston SR, Kelland LR. Farnesyl transferase inhibitors - a novel therapy for breast cancer. Endocr Relat Cancer 2001;8(3):227-35.
    • (2001) Endocr Relat Cancer , vol.8 , Issue.3 , pp. 227-235
    • Johnston, S.R.1    Kelland, L.R.2
  • 66
    • 0036489947 scopus 로고    scopus 로고
    • Current progress on farnesyl protein transferase inhibitors
    • Singh SB, Lingham RB. Current progress on farnesyl protein transferase inhibitors. Curr Opin Drug Discov Devel 2002;5(2):225-44.
    • (2002) Curr Opin Drug Discov Devel , vol.5 , Issue.2 , pp. 225-244
    • Singh, S.B.1    Lingham, R.B.2
  • 67
    • 0001139688 scopus 로고    scopus 로고
    • NCIC CTG IND. 128: A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional Cell Carcinoma of the urothelial tract failing prior chemotherapy
    • Abstract
    • Winquist E, Moore MJ, Chi K, Ernst S, Hirte H, Iscoe N, et al. NCIC CTG IND. 128: A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional Cell Carcinoma of the urothelial tract failing prior chemotherapy. Proc Annu Meet Am Soc Clin Oncol 2001;20(1):197a [Abstract].
    • (2001) Proc Annu Meet Am Soc Clin Oncol , vol.20 , Issue.1
    • Winquist, E.1    Moore, M.J.2    Chi, K.3    Ernst, S.4    Hirte, H.5    Iscoe, N.6
  • 68
    • 0036489885 scopus 로고    scopus 로고
    • Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - Clinical progress
    • Renhowe PA. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - clinical progress. Curr Opin Drug Discov Devel 2002;5(2):214-24.
    • (2002) Curr Opin Drug Discov Devel , vol.5 , Issue.2 , pp. 214-224
    • Renhowe, P.A.1
  • 69
    • 0036500831 scopus 로고    scopus 로고
    • Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy
    • Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94(5):1593-611.
    • (2002) Cancer , vol.94 , Issue.5 , pp. 1593-1611
    • Herbst, R.S.1    Shin, D.M.2
  • 70
    • 0036214044 scopus 로고    scopus 로고
    • The ErbB receptor family: A therapeutic target for cancer
    • de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002;8(4):S19-26.
    • (2002) Trends Mol Med , vol.8 , Issue.4
    • De Bono, J.S.1    Rowinsky, E.K.2
  • 71
    • 0002823211 scopus 로고    scopus 로고
    • Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
    • Abstract
    • Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Annu Meet Am Soc Clin Oncol 2001;20(1):3a [Abstract].
    • (2001) Proc Annu Meet Am Soc Clin Oncol , vol.20 , Issue.1
    • Saltz, L.1    Rubin, M.2    Hochster, H.3    Tchekmeydian, N.S.4    Waksal, H.5    Needle, M.6
  • 72
    • 0035409904 scopus 로고    scopus 로고
    • IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
    • Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001;1(4):719-32.
    • (2001) Expert Opin Biol Ther , vol.1 , Issue.4 , pp. 719-732
    • Herbst, R.S.1    Kim, E.S.2    Harari, P.M.3
  • 73
    • 0034489116 scopus 로고    scopus 로고
    • Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
    • Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6(12):4874-84.
    • (2000) Clin Cancer Res , vol.6 , Issue.12 , pp. 4874-4884
    • Inoue, K.1    Slaton, J.W.2    Perrotte, P.3
  • 74
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92.
    • (2001) N Engl J Med , vol.344 , Issue.11 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3    Fuchs, H.4    Paton, V.5    Bajamonde, A.6
  • 75
    • 0034890387 scopus 로고    scopus 로고
    • Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors
    • Jimenez RE, Hussain M, Bianco FJJ, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7(8):2440-7.
    • (2001) Clin Cancer Res , vol.7 , Issue.8 , pp. 2440-2447
    • Jimenez, R.E.1    Hussain, M.2    Bianco, F.J.J.3    Vaishampayan, U.4    Tabazcka, P.5    Sakr, W.A.6
  • 76
    • 0034879275 scopus 로고    scopus 로고
    • Mechanism of action of anti-HER2 monoclonal antibodies
    • Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001;12(Suppl 1):S35-41.
    • (2001) Ann Oncol , vol.12 , Issue.1 SUPPL.
    • Baselga, J.1    Albanell, J.2
  • 77
    • 0036721561 scopus 로고    scopus 로고
    • Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    • Gandour-Edwards R, Lara PNJ, Folkins AK, LaSalle JM, Beckett L, Li Y, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95(5):1009-15.
    • (2002) Cancer , vol.95 , Issue.5 , pp. 1009-1015
    • Gandour-Edwards, R.1    Lara, P.N.J.2    Folkins, A.K.3    LaSalle, J.M.4    Beckett, L.5    Li, Y.6
  • 79
    • 0038786580 scopus 로고    scopus 로고
    • Apoptosis-targeted therapies for cancer
    • Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3(1):17-22.
    • (2003) Cancer Cell , vol.3 , Issue.1 , pp. 17-22
    • Reed, J.C.1
  • 80
    • 0036716281 scopus 로고    scopus 로고
    • The Bcl-2 family: Regulators of the cellular life-or-death switch
    • Cory S, Adams J. The Bcl-2 family: regulators of the cellular life-or-death switch. Nature Reviews 2002;2:647-56.
    • (2002) Nature Reviews , vol.2 , pp. 647-656
    • Cory, S.1    Adams, J.2
  • 81
    • 0035678781 scopus 로고    scopus 로고
    • A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
    • Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001;7(12):3920-7.
    • (2001) Clin Cancer Res , vol.7 , Issue.12 , pp. 3920-3927
    • Chi, K.N.1    Gleave, M.E.2    Klasa, R.3    Murray, N.4    Bryce, C.5    Lopes De Menezes, D.E.6
  • 82
    • 0035529043 scopus 로고    scopus 로고
    • Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy
    • Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Lunec J, et al. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys 2001;51(5):1234-40.
    • (2001) Int J Radiat Oncol Biol Phys , vol.51 , Issue.5 , pp. 1234-1240
    • Qureshi, K.N.1    Griffiths, T.R.2    Robinson, M.C.3    Marsh, C.4    Roberts, J.T.5    Lunec, J.6
  • 83
    • 0032521376 scopus 로고    scopus 로고
    • Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53
    • Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58(6):1090-4.
    • (1998) Cancer Res , vol.58 , Issue.6 , pp. 1090-1094
    • Cote, R.J.1    Dunn, M.D.2    Chatterjee, S.J.3    Stein, J.P.4    Shi, S.R.5    Tran, Q.C.6
  • 84
    • 0030011128 scopus 로고    scopus 로고
    • Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
    • Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381(6584):713-6.
    • (1996) Nature , vol.381 , Issue.6584 , pp. 713-716
    • Waldman, T.1    Lengauer, C.2    Kinzler, K.W.3    Vogelstein, B.4
  • 85
    • 0033887925 scopus 로고    scopus 로고
    • Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinoma
    • Komhoff M. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinoma. Am J Pathol 2000;157(1):29-35.
    • (2000) Am J Pathol , vol.157 , Issue.1 , pp. 29-35
    • Komhoff, M.1
  • 86
    • 0034530889 scopus 로고    scopus 로고
    • The contributions of cyclooxygenase-2 to tumor angiogenesis
    • Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer and Metastastis Reviews 2000;19(1-2):19-27.
    • (2000) Cancer and Metastastis Reviews , vol.19 , Issue.1-2 , pp. 19-27
    • Gately, S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.